Literature DB >> 30191023

The 9th Annual Conference of the International Liver Cancer Association (ILCA) 2015.

Jens U Marquardt1,2,1,2, Peter R Galle1,1.   

Abstract

The 9th International Liver Cancer Association Annual Conference was held from 4th to 6th September 2015 in Paris, France, and attracted a record breaking 900 participants from 51 different countries and 386 submitted abstracts from scientists around the globe. The congress provided a comprehensive overview of current developments in primary liver cancers (i.e., hepatocellular carcinoma and cholangiocarcinoma) and covered a broad range of topics from basic science to clinical studies. Following the success of immunotherapies in recent years, a preconference workshop on immunopathogenesis and immunotherapy in hepatocellular carcinoma also took place. This report will provide a subjective summary of selected abstracts presented at the conference.

Entities:  

Keywords:  ILCA 2015; cholangiocellular carcinoma; heptatocellular carcinoma; primary liver cancer

Year:  2015        PMID： 30191023      PMCID： PMC6095313          DOI： 10.2217/hep.15.39

Source DB:  PubMed          Journal:  Hepat Oncol        ISSN： 2045-0923


  19 in total

1.  Trans-ancestry mutational landscape of hepatocellular carcinoma genomes.

Authors:  Yasushi Totoki; Kenji Tatsuno; Kyle R Covington; Hiroki Ueda; Chad J Creighton; Mamoru Kato; Shingo Tsuji; Lawrence A Donehower; Betty L Slagle; Hiromi Nakamura; Shogo Yamamoto; Eve Shinbrot; Natsuko Hama; Megan Lehmkuhl; Fumie Hosoda; Yasuhito Arai; Kim Walker; Mahmoud Dahdouli; Kengo Gotoh; Genta Nagae; Marie-Claude Gingras; Donna M Muzny; Hidenori Ojima; Kazuaki Shimada; Yutaka Midorikawa; John A Goss; Ronald Cotton; Akimasa Hayashi; Junji Shibahara; Shumpei Ishikawa; Jacfranz Guiteau; Mariko Tanaka; Tomoko Urushidate; Shoko Ohashi; Naoko Okada; Harsha Doddapaneni; Min Wang; Yiming Zhu; Huyen Dinh; Takuji Okusaka; Norihiro Kokudo; Tomoo Kosuge; Tadatoshi Takayama; Masashi Fukayama; Richard A Gibbs; David A Wheeler; Hiroyuki Aburatani; Tatsuhiro Shibata
Journal:  Nat Genet       Date:  2014-11-02       Impact factor: 38.330

2.  Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells.

Authors:  Michael F Clarke; John E Dick; Peter B Dirks; Connie J Eaves; Catriona H M Jamieson; D Leanne Jones; Jane Visvader; Irving L Weissman; Geoffrey M Wahl
Journal:  Cancer Res       Date:  2006-09-21       Impact factor: 12.701

Review 3.  From non-A, non-B hepatitis to hepatitis C virus cure.

Authors:  Jean-Michel Pawlotsky; Jordan J Feld; Stefan Zeuzem; Jay H Hoofnagle
Journal:  J Hepatol       Date:  2015-04       Impact factor: 25.083

4.  Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

Authors:  Andrew X Zhu; Joon Oh Park; Baek-Yeol Ryoo; Chia-Jui Yen; Ronnie Poon; Davide Pastorelli; Jean-Frederic Blanc; Hyun Cheol Chung; Ari D Baron; Tulio Eduardo Flesch Pfiffer; Takuji Okusaka; Katerina Kubackova; Jorg Trojan; Javier Sastre; Ian Chau; Shao-Chun Chang; Paolo B Abada; Ling Yang; Jonathan D Schwartz; Masatoshi Kudo
Journal:  Lancet Oncol       Date:  2015-06-18       Impact factor: 41.316

5.  Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.

Authors:  Joshua N Honeyman; Elana P Simon; Nicolas Robine; Rachel Chiaroni-Clarke; David G Darcy; Irene Isabel P Lim; Caroline E Gleason; Jennifer M Murphy; Brad R Rosenberg; Lydia Teegan; Constantin N Takacs; Sergio Botero; Rachel Belote; Soren Germer; Anne-Katrin Emde; Vladimir Vacic; Umesh Bhanot; Michael P LaQuaglia; Sanford M Simon
Journal:  Science       Date:  2014-02-28       Impact factor: 47.728

Review 6.  Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.

Authors:  Virginia Hernandez-Gea; Sara Toffanin; Scott L Friedman; Josep M Llovet
Journal:  Gastroenterology       Date:  2013-01-09       Impact factor: 22.682

7.  Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.

Authors:  Wei Gao; Heungnam Kim; Mingqian Feng; Yen Phung; Charles P Xavier; Jeffrey S Rubin; Mitchell Ho
Journal:  Hepatology       Date:  2014-06-18       Impact factor: 17.425

Review 8.  HCC therapies--lessons learned.

Authors:  Marcus-Alexander Wörns; Peter Robert Galle
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-02-04       Impact factor: 46.802

9.  Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

Authors:  Armando Santoro; Lorenza Rimassa; Ivan Borbath; Bruno Daniele; Stefania Salvagni; Jean Luc Van Laethem; Hans Van Vlierberghe; Jörg Trojan; Frank T Kolligs; Alan Weiss; Steven Miles; Antonio Gasbarrini; Monica Lencioni; Luca Cicalese; Morris Sherman; Cesare Gridelli; Peter Buggisch; Guido Gerken; Roland M Schmid; Corrado Boni; Nicola Personeni; Ziad Hassoun; Giovanni Abbadessa; Brian Schwartz; Reinhard Von Roemeling; Maria E Lamar; Yinpu Chen; Camillo Porta
Journal:  Lancet Oncol       Date:  2012-11-20       Impact factor: 41.316

10.  Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.

Authors:  Kornelius Schulze; Sandrine Imbeaud; Eric Letouzé; Ludmil B Alexandrov; Julien Calderaro; Sandra Rebouissou; Gabrielle Couchy; Clément Meiller; Jayendra Shinde; Frederic Soysouvanh; Anna-Line Calatayud; Roser Pinyol; Laura Pelletier; Charles Balabaud; Alexis Laurent; Jean-Frederic Blanc; Vincenzo Mazzaferro; Fabien Calvo; Augusto Villanueva; Jean-Charles Nault; Paulette Bioulac-Sage; Michael R Stratton; Josep M Llovet; Jessica Zucman-Rossi
Journal:  Nat Genet       Date:  2015-03-30       Impact factor: 38.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.